US Stock Market Closed

Dashboard

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity
Analyst Opinion

H

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

About

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

CEO

Kevin Lee

Employees

72

Industry

-

Sector

-

Headquarters

Cambridge

Exchange

NASDAQ

Summary Stats

Market Cap

832M

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 7 analysts

High

$35.00

Average

$27.71

Low

$22.00

Ratings calculated by 7 analysts

Buy

7

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Missed by -$0.07

Actual

-$0.96 -7.9%

Consensus

-0.89

Report Date

Year Ago

-0.59

Year Ago Change %

Down 62%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites